Malariotherapy and the treatment of neurosyphilis

Inducing one disease to treat another

General paresis was a devastating late manifestation of syphilis affecting the brain.^[2] In 1917, Viennese psychiatrist Julius Wagner-Jauregg began using malaria infection to induce repeated fever in patients for whom medicine had few alternatives.^[2] The Nobel Prize awarded him its 1927 physiology or medicine prize for the therapeutic value of malaria inoculation in treating dementia paralytica, the period term for general paresis.^[1]

The approach converted an infection into a treatment intended to alter the course of another disease. It therefore created two clinical problems at once: whether general paresis improved and whether the induced malaria could be controlled. Availability of quinine did not make the second problem disappear.

Reported benefits and treatment deaths

Patients were infected with malaria, often Plasmodium vivax, to generate fever and then received quinine to end the infection.^[2] The goal was not a belief that malaria was harmless: it was a gamble that fever treatment could improve outcomes in a disease that was otherwise generally fatal. Historical reviews document reported remissions as well as treatment deaths.^[2][3] Estimates vary by setting and era; one modern review gives a range of roughly 5–15 percent for malaria-treatment mortality rather than a universal 15 percent.^[3]

A historical report could classify a patient as partly improved without demonstrating eradication of syphilis or permanent recovery. Selection of patients, additional drugs and follow-up all affected what counted as success. Comparing remission percentages across institutions requires those definitions rather than assuming that every reported improvement meant the same thing.

Interpreting remission and malaria risk

Early reports compared outcomes with the grim natural course of general paresis and described complete or partial remissions in some patients. They were not modern randomized trials: case selection, concurrent arsenical drugs, varied malaria strains, and changing definitions of improvement complicate comparisons.^[2] Quinine was used after fever episodes.^[2] When penicillin became available, it treated the underlying infection without deliberately exposing patients to malaria, changing the therapeutic balance.

The modern review of malaria mortality examines historical treatment data partly to challenge the description of Plasmodium vivax as benign.^[3] Deliberately induced infections caused serious illness and deaths. The broad historical mortality range describes differing settings, not a dependable risk estimate for a particular patient or a justification for modern use.

Penicillin changed the comparison

Penicillin transformed syphilis treatment and displaced malariotherapy.^[2] Treating the underlying infection no longer required deliberately exposing a patient to malaria. The earlier treatment’s reported benefits, deaths and limitations remain part of the history of psychiatry and infectious disease.

Once penicillin could treat the underlying infection, the balance no longer concerned malaria therapy versus the untreated natural history alone. It concerned a hazardous intervention versus an effective antimicrobial alternative. That shift explains displacement of the method more clearly than treating the Nobel award as a permanent endorsement of its use.